Silence Therapeutics plc Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
Silence Therapeutics plc (SLN) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of -GBP 174.00 thousand for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-13.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2024-03-13
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2023-12-31 | -174.00K GBP 20-F · filed 2024-03-13 |
| 2022-12-31 | -190.00K GBP 20-F · filed 2023-03-15 |
| 2021-12-31 | -211.00K GBP 20-F · filed 2022-03-17 |
| 2020-12-31 | -402.00K GBP 20-F/A · filed 2021-04-29 |